A Case of Steroid-Responsive Multisystem Inflammatory Syndrome in Adults With SARS-CoV-2
dc.contributor.author | Shishido, Akira | |
dc.contributor.author | Hanna, Peter, M.D. | |
dc.contributor.author | Engelmann, Alexander | |
dc.contributor.author | Kaur, Harpreet | |
dc.contributor.author | Talwani, Rohit | |
dc.date.accessioned | 2023-11-03T17:15:17Z | |
dc.date.available | 2023-11-03T17:15:17Z | |
dc.date.issued | 2022-05-17 | |
dc.identifier.uri | http://hdl.handle.net/10713/21000 | |
dc.description | The article processing charges (APC) for this open access article were partially funded by the Health Sciences and Human Services Library's Open Access Publishing Fund for Early-Career Researchers. | en_US |
dc.description.abstract | While the COVID-19 pandemic continues to evolve, different phenotypic variants of the disease are being recognized.Multisystem inflammatory syndrome in adults is an emerging entity that has yet to be fully characterized. The syndrome involves extrapulmonary multiorgan failure with hyperinflammation that typically affects young healthy males, approximately 2 to 12 weeks after infection with SARS-CoV-2. There are no formal guidelines for management, although the syndrome appears responsive to immunomodulators and supportive care. Clinicians should be aware of this unusual and severe clinical entity and the general principles of its management. | en_US |
dc.language.iso | en_US | en_US |
dc.relation.ispartof | Annals of Internal Medicine Clinical Cases | en_US |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | multisystem inflammatory syndrome | en_US |
dc.subject.mesh | Inflammation | en_US |
dc.subject.mesh | COVID-19 | en_US |
dc.title | A Case of Steroid-Responsive Multisystem Inflammatory Syndrome in Adults With SARS-CoV-2 | en_US |
dc.type | Article | en_US |
refterms.dateFOA | 2023-11-03T17:15:18Z |